Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer
Quarterly Journal of Nuclear Medicine and Molecular Imaging , Volume 56 - Issue 5 p. 468- 475
Aim. Prostate cancer (PC) is a major health problem. The Gastrin-Releasing Peptide Receptor (GRPR) offers a promising target for staging and monitoring of PC since it is overexpressed in PC and not in normal prostatic tissue. To improve receptor-mediated imaging we investigated the impact of various experimental conditions on pharmacokinetics using the Indium-111 labelled bombesin (BN) analogue AMBA. Besides frequently used androgen-resistant PC-3 also the clinically more relevant androgen sensitive VCaP celline was used as human PC xenograft in nude mice. Methods. Non-purified [111In]AMBA was compared with HPLC-purified [111In]AMBA. Effect of specific activity was studied administrating 0.1MBq [111In] AMBA supplemented with different amounts of AMBA (1-3000pmol). GRPR was saturated with Tyr 4-BN 1 and 4h prior to injection of [111In]AMBA. Results. GRPR-positive tissue showed a significant 2 to 3-fold increase in absolute uptake after HPLC-purification while keeping a stable tumor-to-pancreas ratio. Lowering specific activity resulted in decline in uptake to 43% in tumor, 49% in kidney and 92% in pancreas between 10 and 3000 pmol. Tumor-to-pancreas ratio improved six-fold from 0.1±0 after 10 pmol up to 0.6±0.2 after 3000 pmol (P<0.01). When saturating GRPR 4h prior to [111In]AMBA injection tumor-to-pancreas ratio improved from 0.10±0.3 to 0.22±0.2 (P<0.01) and tumor-to-kidney ratio increased from 0.92±0.16 to 3.45±0.5 (P<0.01). Conclusion. Besides specific peptide characteristics also the experimental conditions, such as HPLC-purification, variations in specific activity and saturation of the GRPR prior to [111In]AMBA administration essentially affect radiopeptide pharmacokinetics. Experimental conditions therefore need to be carefully selected in order to compose ideal standardised protocols for optimal targeting.
|Prostatic neoplasms, Receptors, bombesin, Research design|
|Quarterly Journal of Nuclear Medicine and Molecular Imaging|
|Organisation||Department of Nuclear Medicine|
Schroeder, R.P.J, de Blois, E, de Ridder, C.M.A, van Weerden, W.M, Breeman, W.A.P, & de Jong, M. (2012). Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 56(5), 468–475. Retrieved from http://hdl.handle.net/1765/92252